In part, the disclosure relates to methods of treating myeloproliferativedisorders by administering one or more SerumAmyloid Protein (SAP) proteins. In certain aspects, the method furthercomprises monitoring treatment efficacy by measuringchange in mutant allele burden. In certain aspects, the disclosure relates tomethods of treating myelofibrosis in patientsub-populations who carry myelofibrosis-associated mutations in some of theircells by administering an SAP protein.